Quantcast

Latest Breast cancer treatment Stories

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-06-02 16:26:24

OAKLAND, Calif., June 2, 2014 /PRNewswire/ -- Patients with specific HER2+ breast cancer tumors have a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO Researchers reviewed 16,975 cases of breast cancer diagnosed in Kaiser Permanente patients between 2000 and 2006....

2014-06-02 08:31:43

Results indicate that it's possible for breast cancer patients to receive adequate doses of radiation therapy while undergoing patient-controlled tissue expansion as part of the breast reconstruction process PALO ALTO, Calif., June 2, 2014 /PRNewswire/ -- AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, today reported published results that show that acceptable levels of radiation can be...

2014-05-29 08:29:37

New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in...

2014-05-27 08:29:27

Initial Responses Seen Before Patients Have Completed Treatments; BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a summary of initial data to date in its ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors. The Company reported that over 50% of the patients who have completed at least half of...

2014-05-20 23:09:02

Funds will expand commercialization of market-leading early-stage breast cancer treatment. (PRWEB) May 20, 2014 ALISO VIEJO, Calif: Cianna Medical, Inc., a women’s health company, today announced it has secured a $10 million financing deal with GE Capital’s Healthcare Financial Services business. The funds will be used to further product development efforts in the breast conservation therapy (BCT) market, as well as expand the commercialization of the company’s SAVI® breast...

2014-05-15 08:32:30

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing...

2014-05-14 20:23:48

CLEVELAND, May 14, 2014 /PRNewswire/ -- Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the 50(th) American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago....

2014-05-08 09:30:29

AURORA, the first international molecular screening program for metastatic breast cancer, presented at IMPAKT Breast Cancer Conference While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant...

2014-05-02 08:25:16

Large Study Published in The Oncologist Underscores Test's Value in Guiding Treatment Decisions REDWOOD CITY, Calif., May 2, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX(®) colon cancer decision impact study, demonstrating that Recurrence Score(®) results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.